靶向蛋白降解技术研究进展与展望
投稿时间:2023-03-06  修订日期:2023-05-11  点此下载全文
引用本文:周洛竹,盛春泉.靶向蛋白降解技术研究进展与展望[J].药学实践杂志,2023,41(6):341~351,365
摘要点击次数: 762
全文下载次数: 2501
作者单位E-mail
周洛竹 海军军医大学药学系药物化学教研室, 上海 200433  
盛春泉 海军军医大学药学系药物化学教研室, 上海 200433 shengcq@smmu.edu.cn 
中文摘要:靶向蛋白降解技术(TPD)通过调动细胞内固有的两大蛋白降解机制——泛素-蛋白酶体系统(UPS)或溶酶体途径下调致病靶蛋白,有望克服传统抑制剂的局限性,挑战“难成药”靶点,为药物开发提供新的靶向治疗手段。重点关注多种有前景的靶向蛋白降解技术,包括蛋白水解靶向嵌合体(PROTAC)、分子胶、溶酶体靶向嵌合体(LYTAC)、自噬体绑定化合物(ATTEC)、自噬靶向嵌合体AUTAC和AUTOTAC,分析代表性的案例及其潜在的应用与挑战。
中文关键词:靶向蛋白降解  泛素-蛋白酶体系统  溶酶体途径  药物发现  PROTAC
 
Advances and prospects in targeted protein degradation
Abstract:Targeted protein degradation (TPD) techniques eliminate pathogenic proteins by hijacking the intracellular proteolysis machinery which includes the ubiquitin-proteasome system (UPS) and the lysosomal degradation pathway, holding promise to overcome the limitations of traditional inhibitors and further broaden the target space including many “undruggable” targets, and provide new targeted treatments for drug discovery. In this review, recent advances in a variety of promising TPD strategies were summarized, such as proteolysis targeting chimera (PROTAC), molecular glue, lysosome-targeting chimaera (LYTAC), autophagosome-tethering compound (ATTEC), autophagy-targeting chimera AUTAC and AUTOTAC, particularly. The representative case studies, potential applications and challenges were analyzed.
keywords:targeted protein degradation  ubiquitin–proteasome system  lysosomal degradation pathway  drug discovery  PROTAC
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮